Literature DB >> 10574787

Telomerase as a possible target for anticancer therapy.

C Autexier1.   

Abstract

Telomeres, the termini of chromosomes, provide essential stability to linear eukaryotic chromosomes. The enzyme telomerase is one mechanism that maintains telomeres, and is activated in 85% of human cancer cells. New studies on peptide nucleic acids (PNAs) that inhibit telomerase have demonstrated that unexpected regions of the enzyme can serve as targets for inhibitors. The novel delivery method used expands the utility of PNAs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10574787     DOI: 10.1016/s1074-5521(99)80122-7

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  5 in total

1.  Inhibition of telomerase by 2'-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells.

Authors:  A N Elayadi; A Demieville; E V Wancewicz; B P Monia; D R Corey
Journal:  Nucleic Acids Res       Date:  2001-04-15       Impact factor: 16.971

2.  Expression of hTERT and hTR in cis reconstitutes and active human telomerase ribonucleoprotein.

Authors:  F Bachand; G Kukolj; C Autexier
Journal:  RNA       Date:  2000-05       Impact factor: 4.942

3.  Functional regions of human telomerase reverse transcriptase and human telomerase RNA required for telomerase activity and RNA-protein interactions.

Authors:  F Bachand; C Autexier
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

4.  Combinatorial Effect of Arsenic and Herbal Compounds in Telomerase-Mediated Apoptosis Induction in Liver Cancer.

Authors:  Archana Chaudhary; Sadhan Kumar Bhardwaj; Azmi Khan; Amrita Srivastava; Kislay Kumar Sinha; Mehboob Ali; Rizwanul Haque
Journal:  Biol Trace Elem Res       Date:  2022-10-04       Impact factor: 4.081

5.  Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study.

Authors:  S L Bernhardt; M K Gjertsen; S Trachsel; M Møller; J A Eriksen; M Meo; T Buanes; G Gaudernack
Journal:  Br J Cancer       Date:  2006-10-24       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.